Mahana Therapeutics, a developer of FDA-cleared app-based, digital prescription digital therapeutics treatments for irritable bowel syndrome (IBS), completed a $61 million Series B financing. JAZZ
Mahana Therapeutics, a developer of FDA-cleared app-based, digital prescription digital therapeutics treatments for irritable bowel syndrome (IBS), completed a $61 million Series B financing. JAZZ